A clinical study of the local injection of a freshly manufactured 35 kDa hyaluronan fragment for treating chronic wounds

Abstract

AbstractThis study manufactured a 35 kDa hyaluronan fragment (HA35) by enzymatically degrading high‐molecular‐weight HA using hyaluronidase PH20 derived from bovine testis. The research then examined the therapeutic efficacy of locally administered, tissue‐permeable HA35 in alleviating chronic wounds and their associated neuropathic pain. For 20 patients with nonhealing wounds and associated pain lasting over three months, 100 mg of HA35 was injected daily into the healthy skin surrounding the chronic wound for 10 days. Self‐assessments before and after treatment indicated that HA35 significantly enhanced wound healing. This was evidenced by the formation of fresh granulation tissue on the wounds (p < 0.0001); reduced darkness, redness, dryness, and damage in the skin surrounding the wounds (p < 0.0001), and a decrease in wound size (p < 0.001). Remarkably, HA35 injections alleviated pain associated with chronic wounds within 24 hours (p < 0.0001). It can be concluded that the low‐molecular‐weight hyaluronan fragment HA35 potentially enhances the immune response and angiogenesis during wound healing.